

Infusion Office Preference: \_\_\_\_\_

### PATIENT INFORMATION

Date: \_\_\_\_\_ Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

☐ NKDA Allergies: \_\_\_\_\_

### PROVIDER INFORMATION

Office Contact Name: \_\_\_\_\_ Office Email: \_\_\_\_\_

Prescribing Providers Name: \_\_\_\_\_ Provider NPI: \_\_\_\_\_

Office Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Office Phone Number: \_\_\_\_\_ Office Fax Number: \_\_\_\_\_

### DIAGNOSIS /ICD 10

☐ Moderate to severe immune compromise d/t a medical condition or receipt of immunosuppressive medications or treatments **and** are unlikely to mount an adequate immune response to COVID-19 vaccination **and**:

Not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual with SARS-CoV-2 (ICD 10 for this diagnosis is **Q0224**)

### REQUIRED DOCUMENTATION/Testing

- ☐ This signed order form by the provider
- ☐ Patient demographics AND insurance information

- ☐ Clinical/Progress notes supporting diagnosis above
- ☐ Verification that patient has not had severe hypersensitivity reaction to a COVID-19 vaccine

### MEDICATION ORDERS

☐ 4500mg iv one-time infusion over 60 minutes using 0.2micron inline filter

☐ 4500mg iv every 3 months over 60 minutes using 0.2micron inline filter

Patients must be monitored for 2 hours after the infusion.

Provider Name (Print) \_\_\_\_\_

Physician Signature: \_\_\_\_\_

Date: \_\_\_\_\_

**Fax referral to 866-507-1164 or email to [MICreferral@metroinfusioncenter.com](mailto:MICreferral@metroinfusioncenter.com)**

All information contained in this order form is strictly confidential and will become part of the patient's medical record.

06/30/25